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EDITORIAL 
Negative Symptoms of Schizophrenia: 
The Need for Conceptual Clarity 
When Emil Kraepelin and Eugen Bieuler consolidated the concepts of dementia praecox 
and schizophrenia almost a century ago, they thought negative symptoms represented the 
core psychopathology of the illness. This view was not widely accepted until the past 
decade, which has seen a profusion of studies focusing on negative symptoms. While 
exciting and long overdue, the renewal of interest in these most fundamental symptoms 
of schizophrenia has led to a certain degree of confusion, with numerous competing 
concepts and definitions. Terminology itself has been confounded by the interchangeable 
use of very different terms such as negative, deficit, residual, defect, type II, and Krae- 
pelinian. This lack of conceptual clarity now threatens future progress. In a recent editorial 
in this journal, Carpenter (1991) highlighted problems with the current "concept-free" 
approach to psychopathological categorization with specific reference to the negative- 
symptom construct. He emphasized the need to distinguish between primary and secondary 
negative symptoms and suggested that the deficit-nondeficit dichotomy might be the best 
way to conceptualize negative symptoms. We wish to identify problem areas and clarify 
different negative-symptom cancepts and their implications. Such clarification is essential 
if this construct is to be of value to psychiatry. 
Negative Versus Positive Schizophrenia 
Negative and positive symptoms have been simplistically dichotomized by some authors 
in such a way as to imply that a schizophrenic patient has either positive (positive 
schizophrenia) or negative symptoms (negative schizophrenia). During the past decade, 
this dichotomous model was preeminent (Andreasen 1982, 1990). It implies that positive 
and negative schizophrenia are distinct illnesses or at least distinct forms (subtypes) of 
the same illness. Three testable predictions of this model are: (1) "positive patients" differ 
from "negative patients" on various parameters, (2) such subtyping is longitudinally stable; 
and (3) most schizophrenic patients are classifiable as positive or negative, with mixed 
patients constituting a proportionally small group. These predictions have not been con- 
firmed. While most studies have documented differences between "positive" and "neg- 
ative" patients on a number c~f parameters, this subtyping has not been longitudinally 
consistent (Kay 1990); furthermore a majority of schizophrenic patients have been found 
to be "mixed" (e.g., Andreasen et al 1990). Finally, most investigators observe an 
orthogonal (and not bipolar) relationship between positive and negative syndromes, sug- 
gesting that they represent distinct dimensions (and not subtypes) of schizophrenic illness 
(Pogue-Geile and Keshavan 1990). 
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Type I Versus Type II Schizophrenia 
Crow (1980, 1985) used the distinction between positive and negative symptoms to 
postulate two types of schizophrenia: Type I is characterized by positive symptoms, 
absence of intellectual impairment, normal brain structure, and good response to neu- 
roleptics; and Type II is characterized by prominent negative symptoms, intellectual 
deterioration, enlarged cerebral ventricles, and poor response to neuroleptics. Although 
Type II schizophrenia was originally considered to be a later stage of illness than Type 
I (Crow 1980), Crow later conceptualized these two syndrames as relatively independent 
processes that may coexist in the same patient but follow different time courses and are 
different manifestations of the activity of  the same pathogen (Crow 1985). In contrast to 
the positive/negative subtyping, the Type I/Type H classification is syndrome1 with pos- 
tulated distinct pathophysiologies, but not distinct etiologies; furthermore, as per Crow's 
modified concept (1985), one does not have Type I/Type II patients, but Type I/Type II 
processes, which are not mutually exclusive. It should be noted that there are no oper- 
ational criteria, and the distinction between Type I and Type II schizophrenia is based 
on a series of attributes, only one of which is the presence or absence of negative 
symptoms. 
Deficit Versus Nondeficit Schizophrenia 
Carpenter et al (1988) proposed a distinction between deficit and nondeficit schizophrenia 
based on the presence or absence of primary, enduring, negative symptoms (deficit 
symptoms). Deficit schizophrenic patients were believed to exhibit worse prognosis, 
poorer neuropsychological function, and other neurobiological abnormalities in compar- 
ison to nondeficit schizophrenic patients (Carpenter 1991). This model has enormous 
heuristic merit, but three definitional issues merit further attention: (1) what is the validity 
of the distinction between enduring and nonenduring negative symptoms? (2) what is the 
feasibility of making the distinction between primary and secondary negative symptoms? 
and (3) is deficit best conceptua,qzed ~ a category (deficit-nondeficit) or as a dimension 
(severity of deficit)? 
With regard to the first questior~, most data support the distinction between enduring 
(state-independent, deficit, neur~ '.: ~ptic-refractory) and nonenduring (state-dependent, psy~ 
chotic-phasic, neuroleptic-respor~sive) negative symptoms (Kay 1990, Tandon and Gre- 
den, 1990); enduring negative symptoms generally have the characteristics described for 
Type II schizophrenia. While it is therefore important to delineate the entity of enduring 
negative symptoms, it is unclear as to when these symptoms develop in the course of 
schizophrenia. Some investigators suggest that these symptoms develop premorbidly while 
others suggest that they are part of postpsychotic deterioration in schizophrenia. This 
distinction is important in view of the controversy about the neurodevelopmental versus 
neurodegenerative hypotheses of schizophrenia. Conceivably, there may be both devel- 
opmental and degenerative mechanisms in schizophrenia; the entity of enduring negative 
symptoms may be comprised of two distinct components (premorbid and postpsychotic 
deterioration) derived from them (Bilder et al 1985), Clinical and neurobiological cor- 
relates of these two types of enduring negative syraptoms thus could differ, and distin- 
guishing between them may be important. None of the current negative symptom models 
(including the deficit-nondeficit concept) makes this distinction. 
With regard to the second question, the distinction between primaryand secondary 
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negative symptoms is appealing. There is clear phenomenological overlap between neg- 
ative symptoms and symptoms of depression, neuroleptic-induced extrapyramidal side- 
effects (EPS), and the psychological effects of environmental deprivation, all of which 
occur commonly in the course of schizophrenia. As Carpenter (1991) emphasized in his 
editorial, clinicians/researchers are primarily interested in negative symptoms related to 
core (intrinsic) pathology of schizophrenia in contrast to other sources of negative symp- 
toms. Practical difficulties arise, however, in making distinctions between primary and 
secondary negative symptoms. The relationship between negative and depressive symp- 
toms is not clearly worked out. Data suggest that these constructs probably can be 
measured separately in schizophrenia, but the precise relationship between them is unclear. 
Furthermore, the concurrent presence of negative and depressive symptoms does not 
necessarily imply that the negative symptoms are secondary to the depressive symptoms. 
While there is a phenomenological overlap between akinesia and negative symptoms, 
negative symptoms that respond to anticholinergics or dopaminomimetic agents similarly 
are not necessarily secondary to EPS (Tandon and Greden 1989; Berman and Weinberger 
1990). Teasing out effects of environmental deprivation is similarly difficult. 
The third question addresses the issue of whether deficit is best conceptualized as a 
category (deficit-nondeficit) or as a dimension (severity). Data indicate that increasing 
severity of deficit symptoms is associated with more severe dysfunction and greater 
prevalence of various neurobiological abnormalities in schizophrenia, but is unclear whether 
it delineates a distinct form or subtype of the illness. While the question is unresolved, 
existing data are more consistent with a dimensional view (Daniel and Weinberger 1991). 
Other Negative Symptom Concepts 
Keefe et al (1988, 1991) postulate a distinction between Kraepelinian (deteriorated) versus 
nonKraepelinian (nondeteriorated) schizophrenia. Kraepelinian schizophrenia purportedly 
is associated with more severe negative symptoms, greater familial loading of schizo- 
phrenia spectrum disorders, structural brain abnormalities, and poor response to neuro- 
leptics. The basis of classification in this scheme is outcome and severity of deterioration. 
"Defect" refers to a severely deteriorated state in schizophrenia. "Residual" symptoms, 
while embracing a broader concept, are essentially similar to enduring negative symptoms. 
In Conclusion 
The abundance of research reports generated by the renewed interest in the negative- 
symptom syndrome in schizophrenia may attest to the importance of this construct. 
However, one report often is difficult to compare with another. The concepts described 
above appear similar and overlapping, but they are not interchangeable. All have heuristic 
merit; on the other hand, none are proven or established. Any of the above models can 
be employed to conceptualize negative symptoms, but the model should be clearly stated, 
should be selected a priori, its implications recognized, and suitable rating instruments 
and statistical tests employed. For example, if one wishes to use the positive/negative 
model to conceptualize negative symptoms, one needs to utilize suitable instruments to 
dichotomize patients as positive and negative, and employ appropriate statistical tests to 
test any hypotheses of differences between positive and negative schizophrenic patients. 
Over a dozen rating instruments, each with its own conceptual bias and construct limi- 
tations, are being employed to measure and define these concepts (Silk and Tandon 1990). 
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Rather than further proliferating the number of rating scales to measure this construct, 
there needs to be some consensus in the field about standardized methods of assessment 
in order to permit generalizability of findings. The issue of whether the negative syndrome 
reflects a dimension of pathology in all schizophrenic patients or occurs only in a subgroup 
of schizophrenic patients (the negative subtype) merits further inquiry. The longitudinal 
perspective needs to be borne in mind. When studying the association of negative symp- 
toms with any clinical or neurobiological parameter, the phase of assessment and the 
rating instrument employed to measure negative symptoms are crucial sources of variance. 
Ideally, any relationship should be studied in different phases of the illness to evaluate 
its trait and state components. Finally, investigators should indicate that if one construct 
of negative symptoms was used in a given study, its findings do not automatically 
generalize to offer differing cons~Jcts. 
Over the past decade we have accumulated considerable knowledge about negative 
symptoms. Most data support the utility of the negative-symptom construct as an organ° 
izing principle in schizophrenia. However, confusion prevails. It may even be growing, 
largely attributable to a multiplicity of concepts and the absence of operational definitions 
and standardization. To fully harness the power of this construct in unlocking the mystery 
of schizophrenia we need more systematic and rigorous testing of hypotheses, better use 
of operational definitions, improved standardization, and avoidance of generalizations 
from one construct to another. 
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